Products
Pre-made Cadonilimab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-088
Pre-made Cadonilimab benchmark antibody (Bispecific Mixed mAb and scFv, anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cadonilimab (AK104) is a novel, potential next-generation,first-in-classbi-specificPD-1/CTLA-4immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-088-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-088-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-088-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-088-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-made Cadonilimab benchmark antibody (Bispecific Mixed mAb and scFv, anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) |
| INN Name | Cadonilimab |
| Target | PD-1;CTLA-4 |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1;na |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | Akeso Biopharma |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma |
| Conditions Discontinued | na |
| Development Tech | na |
